Donanemab

About Eli Lilly

Eli Lilly is a mission-driven pharmaceutical giant focused on discovering, developing, and commercializing medicines that address significant unmet medical needs in core therapeutic areas. The company has achieved monumental commercial success with recent blockbusters in diabetes (Mounjaro®/tirzepatide) and obesity (Zepbound®/tirzepatide), while also making historic strides in Alzheimer's disease with the approval of donanemab. Its strategy leverages deep scientific expertise across multiple modalities, a massive and diversified clinical pipeline, and a forward-looking commercial approach that integrates drug delivery with patient support services to secure long-term growth.

Therapeutic Areas